Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease
Myrna Nahas, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Rebecca Karp Leaf(California University of Pennsylvania), Leandra Cole(Beth Israel Deaconess Medical Center), Vincent T. Ho, David Avigan(Beth Israel Deaconess Medical Center), Joseph H. Antin(Dana-Farber Cancer Institute), Jeremy Stewart(Harvard University), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mary Paty Bryant(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Emma Logan(Beth Israel Deaconess Medical Center), Athalia R. Pyzer, Dina Stroopinsky(Beth Israel Deaconess Medical Center), Susan Stephenson(Harvard University), James D. Levine(Beth Israel Deaconess Medical Center), Ayad Hamdan(University of California San Diego), Josie Bazemore(Dana-Farber Cancer Institute), Abigail Washington(Beth Israel Deaconess Medical Center), Amy Joyce(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k